# The RIF1-Long splice variant promotes G1 phase 53BP1 nuclear bodies to protect against replication stress

Lotte P. Watts[1], Toyoaki Natsume[2,3], Yuichiro Saito[2], Javier Garzón[1], Masato T. Kanemaki[2,3], Shin-ichiro Hiraga[1] and Anne D. Donaldson[1,4]

**Author affiliations**

[1] Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, Scotland, UK

[2] Department of Chromosome Science, National Institute of Genetics, Research Organization of Information and Systems (ROIS), Mishima, Shizuoka 411-8540, Japan

[3] Department of Genetics, The Graduate University for Advanced Studies (SOKENDAI), Mishima, Shizuoka 411-8540, Japan

[4]Corresponding author

**Running title:** RIF1 splice variants and replication stress

**Keywords:** RIF1/ DNA replication/ DNA replication stress/splicing

## SUMMARY

**Human RIF1 functions in DNA replication and damage repair. Of clinical interest, RIF1-depleted cells are highly sensitive to replication inhibitors such as Aphidicolin, but the reasons for this sensitivity have been enigmatic. Here we show that RIF1 must be present both during replication stress and in the ensuing recovery period to promote cell survival. RIF1 Long and Short isoforms are produced by alternative splicing. We find that RIF1-Long alone can protect cells against replication inhibition, but RIF1-Short is completely incapable of mediating protection. Consistent with its isoform-specific role in enabling survival, RIF1-Long is specifically required to promote the formation of the 53BP1 nuclear bodies that protect unrepaired damage sites in the G1 phase following replication stress. Overall, our observations show that RIF1 is needed at several cell cycle stages to support genome maintenance following replication insult, with the RIF1-Long isoform playing a previously unsuspected but crucial role in damage site protection during the ensuing G1 phase.**

## INTRODUCTION

The RIF1 protein has emerged as a central regulator of chromosome maintenance, acting in double strand break repair and DNA replication control[1–3]. For its function in double strand break repair, RIF1 is recruited by 53BP1, dependent upon phosphorylation of 53BP1 by ATM[1,2,4]. Together RIF1 and 53BP1 recruit Shieldin and suppress BRCA1 recruitment to damage sites, opposing homologous recombination-based repair and favouring Non-Homologous End Joining[5,6].

RIF1 is also implicated in protecting cells from replication stress[7–9]. Replication stress can be induced by various conditions including drugs such as Aphidicolin, which interrupts replication fork progression by inhibiting the replicative DNA polymerases alpha, delta, and epsilon[10]. Replication stress leads to genomic instability, mutation and eventually disease[11–13], so understanding the cellular response is central for understanding accurate genome duplication and the action of replication inhibitors as anti-cancer drugs[14,15]. RIF1-deficient cells are acutely sensitive to replication stress, in fact appearing to be more sensitive to replication inhibitors than to DSB-inducing agents[8], suggesting that protection from stress is one of the most critical RIF1 functions.

Several roles have been described for RIF1 in replication control. RIF1 acts as a Protein Phosphatase 1 (PP1) 'substrate-targeting subunit'[16] that suppresses replication origin initiation by directing PP1 to dephosphorylate the MCM replicative helicase complex[3,17–20].

RIF1 moreover stimulates origin licensing during G1 phase, and protects replication forks from unscheduled degradation[3,21,22]. However, whether deficiency in these functions accounts for the replication stress sensitivity of cells lacking RIF1 has remained unclear[8,14]. RIF1 also acts in mitosis to maintain genomic stability. During anaphase RIF1 is recruited to ultra-fine bridges (UFBs), along with the BLM and PICH proteins that ensure proper chromosome segregation[23]. UFBs are believed to correspond to stretches of under-replicated DNA that escape checkpoint surveillance and persist into mitosis[24,25]. Unresolved DNA damage that passes to daughter cells causes formation of 53BP1 nuclear bodies during G1 phase, thought to protect the damaged DNA[26–28]. RIF1 has also recently been described as functioning at the midbody during cytokinesis[29].

The human RIF1 transcript undergoes alternative splicing producing two protein isoforms: a long variant of 2,472 amino acids ('RIF1-L'), and a short variant ('RIF1-S') which lacks 26 amino acids close to the C-terminus of the protein[30]. RIF1-S was reported to be more abundant in various cancer cell lines[30], hinting at distinct effects of the isoforms. Although RIF1-L was designated the canonical form, studies using cloned RIF1 have invariably used RIF1-S[1,30–32], without testing for distinct functions of the isoforms.

## RESULTS

### Analysing fluorescent degron-tagged RIF1 reveals highly dynamic cell cycle localisation

We aimed to understand how RIF1 guards against replication stress. First we confirmed in a colony formation assay (CFA) that HEK293 cells depleted for RIF1 are sensitive to the polymerase inhibitor Aphidicolin (Fig. 1A,B). Mouse embryonic fibroblasts that are *RIF1*$^{-/-}$ were also sensitive[2] (Fig. 1C), as were human colon cancer (HCT116) cells deleted for both copies of *RIF1* (Fig. 1D). Doses of Aphidicolin were designed to slow replication fork progression and induce replication stress, as opposed to blocking the cell cycle[8]. These results imply a specific role for RIF1 in protecting cells under replication stress conditions.

Since RIF1 functions at various cell cycle stages, we explored when RIF1 is needed to maintain cell proliferation following replication stress. Specifically, we tested if RIF1 function is required during DNA replication stress, after its occurrence, or both during and after stress. Using Auxin Inducible Degron (AID) technology we constructed a cell line allowing rapid depletion and re-expression of RIF1 at different phases of the cell cycle[33,34]. In an HCT116-based cell line carrying the auxin-responsive degron recognition protein OsTIR1 under DOX control, we N-terminally tagged both RIF1 copies with a degron-Clover construct, termed 'mAC', consisting of a mini-Auxin Inducible Degron and monomer Clover

(a derivative of GFP[35]) (Fig. 2A)[36]. The expressed construct remains under control of the endogenous RIF1 promoter. Western blot analysis indicated that expression levels of mAC-RIF1 in the absence of Auxin were similar to those of endogenous untagged RIF1 (Fig. 2B). Treatment for 24 hr with DOX and Auxin led to near-complete degradation of RIF1, as visualised by Western blotting (Fig. 2B) and microscopically (Fig. 2C). Using flow cytometry analysis of the RIF1-fused mClover tag, we established minimum concentrations of DOX and Auxin to allow effective depletion (Fig. S1A,B). Degradation was largely complete after 3 hr of Auxin treatment (Fig. S1C), while expression was restored to almost normal levels 5 hr after Auxin removal (Fig. S1D). Together, these results confirm the construction of a cell line allowing rapid depletion and re-expression of RIF1.

We visualised mAC-RIF1 based on Clover fluorescence, to test whether tagged protein retained the behaviour of endogenous RIF1. In live-cell imaging experiments we observed a pattern of numerous mAC-RIF1 foci throughout S phase nuclei (Fig. 2D, top row), often with 3-6 prominent foci superimposed on a pattern of more numerous smaller foci, consistent with previous studies[8,30,37]. In prometaphase mAC-RIF1 exhibits a localisation pattern similar to that described for kinetochores (Fig. 2D, second row, showing polar view of condensed chromosomes)[38]. At anaphase, even in unperturbed cells, mAC-RIF1 was frequently at structures apparently corresponding to ultrafine bridges (UFBs). These structures were not stained by conventional DNA dyes (Fig. 2D, third row) but colocalized with BLM, a marker for UFBs (Fig. S2A, bottom panel)[39,40]. At telophase, mAC-RIF1 formed multiple small foci associated with separated chromosomes (Fig. 2D, bottom row). Time-lapse imaging of HCT116 mAC-RIF1 cells containing an mCherry-tagged PCNA (Fig. S2B,C) revealed intense RIF1 foci that accumulated through S phase and G2 (Video 1 and Fig. S2B), but disappeared by metaphase (Video 2 and Fig. S2C, 180-210 min). RIF1 signal was absent for a short period at metaphase, quickly followed by reappearance of numerous smaller foci on telophase chromosomes coupled with localisation at anaphase bridges.

The mAC-RIF1 fusion therefore retains the localisation and functional characteristics of the endogenous RIF1 protein. Its highly dynamic behaviour indicates that RIF1 functions in several cell cycle phases to maintain chromosome stability.

**RIF1 is needed during and after replication stress to promote cell proliferation**

Prolonged auxin-induced degradation of RIF1 caused sensitivity to Aphidicolin, as expected (Fig. 3A). To investigate when RIF1 function is required to protect against the effects of

Aphidicolin, we synchronised cells first in G1 phase with Lovastatin[41,42], and 8 hr after release from Lovastatin added Aphidicolin to induce replication stress (Fig. 3B, upper timeline). The reversible CDK1/cyclin B1 inhibitor RO-3306[43] was simultaneously added, to induce a temporary G2 arrest and prevent cells from proceeding into mitosis. After 28 hr, Aphidicolin and RO-3306 were removed to allow release, and then 4 hr later cells were plated for CFA measurement of cell viability[43]. Synchronisation timings were optimised using flow cytometry analysis of cell cycle progression (Fig. 3C, Fig. S3A).

Within the above synchronisation procedure, we either depleted RIF1 during the S phase Aphidicolin treatment period and re-expressed it for the recovery period (condition I, Fig. 3B), or else expressed RIF1 during the S phase treatment period and depleted it for the recovery period (condition II, Fig. 3B). We included control samples where RIF1 was either expressed or depleted throughout the entire experiment (Fig. 3D, RIF1+ and RIF1-). Cells depleted of RIF1 only during the replication stress treatment period (condition I) showed sensitivity similar to the RIF1-depleted (RIF1-) condition, displaying a surviving fraction of 27%. Cells depleted of RIF1 only during the recovery period (condition II) also showed high sensitivity, again similar to RIF1- with a surviving fraction of 18% (Fig. 3D). A repeat of this experiment (Fig. S3B) produced very similar results.

We performed similar conditional depletion experiments in asynchronous cell populations (as outlined in S3C), and observed comparable results (Fig. S3D, S3E), in that depletion of RIF1 either during or after Aphidicolin treatment led to sensitivity.

To summarise, these results imply that RIF1 must be present during both treatment and recovery to protect cells from the effects of replication stress induced by Aphidicolin. The observation that RIF1 function remains important after a stressed replication period to promote cell survival is consistent with its highly dynamic pattern of localisation through late cell cycle stages (Fig. 2), which suggests that RIF1 operates in chromosome maintenance processes occuring outside of S phase.

**Only the RIF1-Long splice isoform protects cells from replication stress**

The RIF1 messenger RNA undergoes alternative splicing resulting in expression of 'Long' and 'Short' protein isoforms, called RIF1-L and RIF1-S. RIF1-S lacks 26 amino acids corresponding to exon 31 (Fig. 4A, exon 31 shown in red; see Materials & Methods for Exon designation). Although they were reported as showing differential expression in cancer cells, distinct functions of the two isoforms have not previously been examined. We constructed cell lines expressing only mAC-RIF1-L or only mAC-RIF1-S, by inserting at the 3' end of

Exon 29 a 'pre-spliced' cDNA construct consisting of Exons 30-35 including or excluding Exon 31 (Fig. 4A). Clones were selected where both copies of the mAC-RIF1 gene contained the insertion. Western analysis confirmed that these mAC-RIF1-L and mAC-RIF1-S constructs encoded proteins expressed at levels similar to parental mAC-RIF1 (Fig. 4B, lanes 2 & 3). We also constructed a RIF1-knockout cell line (Fig. 4B, lane 4, RIF1-KO).

We found that while the mAC-RIF1-L cell line showed resistance to Aphidicolin very similar to that of the parent mAC-RIF1 cells (Fig. 4C, black and red bars), the mAC-RIF1-S isoform in contrast conferred little protection against drug, producing sensitivity similar to that of cells lacking RIF1 altogether (Fig. 4C, grey and open bars). This result established that only RIF1-L can protect cells from replication stress caused by Aphidicolin, and that RIF1-S is ineffective in this role.

To confirm this finding in a different cell line, we used HEK293-derived stable cell lines with siRIF1-resistant cDNA constructs encoding either RIF1-L or RIF1-S, expressed under DOX control (Fig. S4A,B,C)[3]. We found that also in this cell line RIF1-L was able to protect against Aphidicolin treatment, while RIF1-S could not (Fig. 4D, filled red and grey bars).

Examining the previously described mechanisms through which RIF1 directly controls DNA replication, RIF1-L and RIF1-S appeared equally functional. In particular, both isoforms are equally effective in preventing hyperphosphorylation of the MCM complex (Fig. 4E) and protecting blocked replication forks (Fig. 4F). RIF1-S can therefore repress origin activation and protect nascent DNA but cannot safeguard cells from Aphidicolin treatment, implying that responding to replication stress demands a further RIF1-mediated mechanism to promote cell survival, probably one that operates after the period of stress (Fig. 3) and that specifically requires RIF1-L (Fig. 4C, D).

In both its origin repression and nascent DNA protection functions, RIF1 acts as a PP1 substrate-targeting subunit[3,18,44]. To further test for separability of the effect of RIF1 in replication stress survival from its known roles in replication control, we investigated whether PP1 interaction is essential for RIF1-L to protect against Aphidicolin treatment. We used the HEK293 cell line expressing a version of RIF1-L mutated at the PP1 interaction motifs to prevent PP1 interaction[3]. This 'RIF1-L-pp1bs' protein was almost as effective as wild-type RIF1-L in conferring resistance to Aphidicolin (Fig. S5), indicating that RIF1-L acts largely independent of PP1 function in protecting cells from the effects of Aphidicolin. This independence from PP1 reinforces the evidence that the function of RIF1 in protecting

from replication stress is distinct from its previously known roles in replication control, which do require PP1.

**RIF1-Long promotes 53BP1 nuclear body formation in G1 phase**

We therefore considered other routes through which RIF1 might promote survival after Aphidicolin treatment, focusing especially on events occurring after the replication stress period itself. UFBs form after replication stress, but we found no clear difference in localization of RIF1-L and RIF1-S to UFBs in mitotic cells (not shown). A further consequence of replication stress is the formation of large 53BP1 nuclear bodies in the subsequent G1 phase, which protect unreplicated DNA damaged by chromosome breakage at mitosis[27,28]. We examined the formation of 53BP1 nuclear bodies in cells lacking RIF1-L, RIF1-S, or both RIF1 isoforms 12 hr after Aphidicolin treatment, limiting our analysis to G1 phase cells by counting only those that were cyclinA2-negative. The parental (mAC-RIF1) cell line showed an elevated fraction of cells with multiple large 53BP1 nuclear bodies (Fig. 5A top row, Fig. 5B, black bars and Fig. S6A top left panel), as expected. Notably, RIF1 was often co-localised with these bodies (Fig. 5A top row and Fig. 5C). In contrast, a reduced number of 53BP1 nuclear bodies was observed in RIF1-KO cells (Fig. 5A bottom row, Fig. 5B open bars, Fig. S6A bottom right panel), demonstrating that RIF1 contributes to the formation of 53BP1 bodies after replication stress. Examining the cell lines expressing only Long or Short RIF1 isoforms, we found that mAC-RIF1-L localised normally with 53BP1 bodies, and supported their formation at a near normal rate (Fig. 5A second row, 5B,C red bars and Fig. S6A top right panel). In contrast, the number of 53BP1 nuclear bodies formed in mAC-RIF1-S cells was similar to that in RIF1-KO cells, and mAC-RIF1-S showed reduced co-localisation with the 53BP1 bodies (Fig. 5A third row, 5B,C grey bars and Fig. S6A bottom left panel). The two RIF1 isoforms therefore differ in their effectiveness in promoting 53BP1 nuclear body formation following replication stress, with RIF1-L but not RIF1-S functional in this role. Since 53BP1 nuclear bodies are known to protect DNA damaged as a consequence of Aphidicolin treatment[27], the defect in 53BP1 body formation when RIF1-L is not available is likely to be a major factor in the replication stress sensitivity of RIF1-deficient cells, and can explain the isoform specificity of the replication stress protection function of RIF1.

**DISCUSSION**

We sought in this study to understand mechanisms through which RIF1 protects against interruption to replication. In testing the function of the RIF1 isoforms, we found that RIF1-L is able to protect against replication stress while RIF1-S cannot. This deficiency of RIF1-S function was initially surprising, since RIF1-S appears competent to fulfil the known functions of RIF1 in DNA replication management—in particular RIF1-S is able to support replication licensing and control MCM phosphorylation (Fig. 4E)[3], and to protect against nascent DNA degradation (Fig. 4F). Consistently however, all of these known functions of RIF1 in replication control (promotion of replication licensing, control of MCM phosphorylation, and nascent DNA protection) depend on PP1 recruitment by RIF1[3,18,21]; while we find that protection against replication stress does not require PP1 interaction (Fig. S5), again suggesting that the role of RIF1 in protecting from replication stress might involve previously undescribed mechanisms.

Testing the effects of conditional depletion in synchronised cultures revealed that RIF1 is still needed after a period of replication stress to guard against toxicity, implying that protection from Aphidicolin involves a further function of RIF1. We therefore investigated whether RIF1 operates in post-S phase replication stress response pathways, a line of enquiry that revealed a new function for RIF1 in promoting the assembly of 53BP1 nuclear bodies (Fig. 5). This requirement for RIF1 for 53BP1 nuclear body assembly represents a surprising role reversal from the order of protein assembly in double-strand break repair, where RIF1 recruitment depends on 53BP1[1,2,4]. Remarkably, we found that RIF1-L but not RIF1-S can function in promoting 53BP1 body formation, potentially explaining the specific requirement for RIF1-L in protecting against replication stress, since 53BP1 body assembly represents an important step in correct handling of stress-associated damage to enable ongoing proliferation. RIF1-L may directly promote 53BP1 body assembly, or possibly assist with the transit of damaged sites through to G1 phase to allow such protective bodies to form. Presently we do not understand the molecular mechanistic differences between RIF1-L and RIF1-S, or how the apparently small difference between the isoforms (the inclusion or exclusion of just 26 amino acids) either permits or prevents 53BP1 nuclear body formation. One intriguing possibility is that RIF1-L is involved in the phase separation of 53BP1[45] recently described as important for assembling G1 phase nuclear bodies. The findings described here explain however that RIF1 contributes to recognising under-replicated and unrepaired sites for special protection and handling later in the chromosome cycle—in particular for delayed replication that guards against unscheduled recombinational repair to prevent the formation of pathological intermediates, as recently described[46]. Overall, this

study highlights the multifunctional role of RIF1 in ensuring chromosome maintenance to promote the survival and proliferation of cells after replication stress, emphasising the importance of RIF1 for determining response to replication-inhibiting chemotherapeutic drugs.

## Materials and Methods

### Cell lines used

MEF RIF1$^{+/+}$ and MEF RIF1$^{-/-}$ cell lines were as previously described[2].

Stable HEK293 Flp-In T-Rex GFP and GFP-RIF1-S cell lines were as described[1,3]. Constructed using the same procedure were cell lines: HEK293 Flp-In T-Rex GFP-RIF1-L and HEK293 Flp-In T-Rex GFP-RIF1-L-pp1bs**.**

The HCT116 mAC-RIF1 cell line was constructed as described[33,36]. HCT116 mAC-RIF1-L, HCT116 mAC-RIF1-S and HCT116 RIF1 KO cells were constructed as described below. HCT116 mAC-RIF1 mCherry-PCNA was constructed by introducing the mCherry-PCNA construct under control of the EF1 alpha promoter using the piggyBac system[47].

### HEK293 cell lines and culture conditions

HEK293-derived cell lines were cultivated in Dulbecco's Modified Eagle's Minimal medium supplemented with 10% foetal bovine serum (tetracycline-free), 100 U/ml penicillin, and 100 μg/ml streptomycin at 5% $CO_2$ and ambient $O_2$ at 37°C. Appropriate antibiotics were added for selection of integrated constructs.

To construct cell lines, pOG44[48] and pcDNA5/FRT/TO-based plasmids carrying the RIF1-L or RIF1-L-pp1bs gene were mixed in 9:1 molar ratio and used for transfection of Flp-In T-Rex 293 cells (Invitrogen) with Lipofectamine 3000 (Invitrogen). Transfections and hygromycin B selection of stably transfected cells were performed as described by the manufacturer. Clones were tested for doxycycline-dependent induction of GFP fusion proteins by western blot and microscopy.

To assess the effect of ectopically expressing RIF1, cells were transfected with either control siRNA or siRNA against human RIF1. 2 days later, cells were split with addition of 1 μg/ml DOX then incubated for 24 hr to induce expression of GFP-RIF1 variant proteins. siRNA transfection was carried out using Lipofectamine RNAiMAX (Invitrogen) as described by the manufacturer. siRNA used were Human RIF1 siRNA (Dharmacon, D-

027983-02) and Control siRNA against Luciferase (Dharmacon, D-001100-01). Synonymous base mutations in the ectopically expressed GFP-RIF1 constructs make them resistant to siRNA targeted against endogenous RIF1[1]. RIF1 expression was assessed by western blot using RIF1 and GFP antibodies.

**HCT116 cell lines and culture conditions**

HCT116-derived cells were cultivated in McCoys 5A medium supplemented with 2 mM L-glutamine, 10% foetal bovine serum (tetracycline-free), 100 U/ml penicillin, and 100 µg/ml streptomycin at 5% $CO_2$ and ambient $O_2$ at 37°C.

*HCT116 mAC-RIF1*

To construct miniAID-mClover-fused RIF1 stable cell lines, HCT116 cells expressing the auxin-responsive F-box protein *Oryza sativa* TIR1 (OsTIR1) under the control of a Tet promoter were transfected using FuGENE HD (Promega) with a CRISPR/Cas9 plasmid targeting nearby the 1st ATG codon of the *RIF1* gene (5'-TCTCCAACAGCGGCGCGAGGggg-3') together with a donor plasmid based on pMK345[36], that contains a cassette (hygromycin resistance marker, self-cleaving peptide P2A, and mAID–mClover[36]) flanked by 500bp homology arms. Two days after transfection cells were diluted in 10 cm dishes, to which 100 µg/mL of Hygromycin B Gold (Invivogen) was added for selection. After 10-12 days, colonies were picked for further selection in a 96-well plate. Bi-allelic insertion of the donor sequence was checked by genomic PCR. Clones were tested for RIF1 expression and AID-mediated degradation of RIF1 by western blot, flow cytometry and microscopy.

To induce degradation of miniAID-mClover-fused RIF1, OsTIR1 expression was first induced by 0.2 µg/ml DOX added to the culture medium, to produce a functional SCF (Skp1–Cullin–F-box) ubiquitin ligase that directs degradation of an AID-tagged protein[33,34]. After 24 hr, 10 µM Auxin (indole-3-acetic acid; IAA) was added to the culture medium to promote the interaction of mAC-RIF1 with SCF-OsTIR1, driving ubiquitination and mAC-RIF1 degradation. To suppress premature degradation of RIF1 in the presence of DOX, 100 µM of the TIR1 inhibitor Auxinole was added[36,49]. In subsequent depletion experiments we used a regime in which DOX was first added in the presence of Auxinole, and then Auxinole was replaced with Auxin. Optimisation of DOX and Auxin concentrations is shown in Figure S1A and B. Unless otherwise stated, the above-mentioned drug concentrations were used throughout.

*HCT116 mAC-RIF1-L/-S*

HCT116 mAC-RIF1 cells were transfected with a CRISPR/Cas9 plasmid targeting the C-terminus of exon 29 of the *RIF1* gene (5'-CATCACCTGTTAATAAGGTAagg-3') together with a donor plasmid, containing the cDNA of the C-terminal part of RIF1 (exons 30 to 35) with exon 31 (mAC-RIF1-L) or without (mAC-RIF1-S), followed by a Neomycin resistance marker (Figure 4A). Transfection and clonal selection were carried out as described above. Clones were tested for RIF1 expression by western blot.

*HCT116 RIF1 KO*

HCT116 cells were transfected with the same CRISPR/Cas9 plasmid that was used to construct HCT116 mAC-RIF1 cells, targeting near the 1st ATG codon of the *RIF1* gene (sequence as above). Simultaneously transfected was a donor plasmid containing a hygromycin resistance marker flanked by 500bp homology arms. Transfection and clonal selection was carried out as described above. Clones were tested for loss of RIF1 expression by western blot.

**PCR primers**

The following PCR primers were used to construct pcDNA5/FRT/TO-GFP-RIF1-L:

SH572: 5' – CTATGGAATTGAATGTAGGAAATGAAGCTAGC – 3'

SH593: 5' – ACCGAGCTCGGATCGATCACCATGACGGCCAGGG – 3'

SH594: 5' – GCCGCGGATCCGAATTCTAAATAGAATTTTCATGGGATGG – 3'

SH595: 5' – GCTACGTGATCCTGGGGACAGAAATCCTTTGGCTGAAGTGGTATTATGCTTAGATTGTGTAGTAGGAGAAG – 3'

SH596: 5' – TCCCCAGGATCACGTAGCCCTAAATTTAAGAGCTCAAAGAAGTGTTTAATTTCAGAAATGGCCAAAG – 3'

SH597: 5' – GATCAGTTATCTATGCGGCCG – 3'

The following PCR primers were used to amplify genomic DNA for the homology arms for the mAC-RIF1 donor plasmid pMK345:

HA1 For: 5'- ccgggctgcaggaattcgatTAGGAGGGAGCGCGCCGCACGCGTG – 3'

HA1 Rev: 5' – ggctttttcatggtggcgatCACCCTGAGGCCCGAACCGGAAGAG – 3'

HA2 For: 5'- gctggtgcaggcgccggatccATGACGGCCAGGGGTCAGAGtCCCCTCGCGCC – 3'

HA2 Rev: 5' – acggtatcgataagcttgatCTCTGGGTAGCCACATTTTCCCAAC – 3'

The following PCR primers were used to amplify genomic DNA for the homology arms for the RIF1 KO donor plasmid pMK194:
HA1 For: (see above)
HA3 Rev: 5' - tcgctgcagcccgggggatcGGGGGCTCTGACCCCTGGCCGTCATGTCGG – 3'
HA4 For: 5' – aagcttatcgataccgtcgaCTTTGGAAGACCCTTCTGCCTCCCATGGAG – 3'
HA2 Rev: (see above)

The following primers were used to amplify the C-terminal portion of either pcDNA5/FRT/TO-GFP-RIF1-L or pcDNA5/FRT/TO-GFP-RIF1 for the mAC-RIF1-L and mAC-RIF1-S donor plasmids:
5' – AAATCTCATCACCTGTTAATAAG – 3'
5' – acaagttaacaacaacaattCTAAATAGAATTTTCATGGGATGGT – 3'

The following primers were used to amplify the homology arms for the mAC-RIF1-L and mAC-RIF1-S donor plasmids:
5' – ATGCAgagctcGAAACAGAGAATGAGGGCATAACTA – 3'
5' – ATGCAggtaccATTCATTCAACAAACTATGTGCAAG – 3'

**Plasmids used for cell line constructions**

The RIF1 long variant cDNA (RIF1-L; NCBI RefSeq NM_018151.4) encodes a 2,472-amino acid protein, while the short variant (RIF1-S; RefSeq NM_001177663.1) lacks the 78-nucleotide stretch corresponding to exon 31[30]. We designate the exon containing the RIF1 ATG start codon as "exon 1", so that our "exon 31" corresponds to "exon 32" of RefSeq NM_018151.4.

The GFP-RIF1 constructs used in this study are based on pcDNA5/FRT/TO-GFP-RIF1[1], which carries human RIF1-S cDNA with GFP fused at its N-terminus. To construct pcDNA5/FRT/TO-GFP-RIF1-L, a PCR fragment containing RIF1-S cDNA was amplified from pcDNA5/FRT/TO-GFP-RIF1 using primers SH593 and SH594, and cloned into pIRESpuro3 vector (linearised by EcoRV and EcoRI) using In-Fusion HD cloning system, to create plasmid pSH1009. The NheI-NotI fragment of the plasmid pSH1009 was replaced by two PCR fragments amplified by SH572 & SH595 and SH596 & SH597 respectively using In-Fusion HD system, to construct pSH1011 which has RIF1-L cDNA. The NheI-PspOMI

fragment of pcDNA5/FRT/TO-GFP-RIF1 was replaced by NheI-NotI fragment of the pSH1011 plasmid to construct pcDNA5/FRT/TO-GFP-RIF1-L.
Construction of a GFP-RIF1-S-pp1bs plasmid was previously described[3]. The GFP-RIF1-L-pp1bs construct was made following a similar strategy.

The plasmid pX330-U6-chimeric_BB-CBh-hSPCas9 from Feng Zhang (Addgene, 42230)[50] was used to construct the CRISPR/Cas vector for the guide RNA (sequence as above) according to the protocol of Ran et al[51]. Donor plasmids were based on pBluescript and constructed as described[33,36]. Primers for amplification of the homology arms and cDNA from RIF1-L and RIF1-S are listed under PCR primers.

**Protein extraction and western blotting**

To prepare whole cell protein extracts, cells were trypsinised and washed with Dulbecco's Phosphate-Buffered Saline (PBS) before treating with lysis buffer (10 mM Tris pH 7.5, 2 mM EDTA) containing a protease and phosphatase inhibitor cocktail (Roche). Chromatin-enriched protein fractions were prepared essentially as described[52]. Protein concentrations were determined using the Bio-Rad RC-DC protein assay kit. Equal amounts of total proteins were loaded in each lane and loading was confirmed by Ponceau S staining. Proteins were transferred to PVDF membrane using the Trans-Blot Turbo Blotting System (Bio-Rad) and detected by Clarity Western ECL blotting substrate (Bio-Rad) and the Bio-Rad Chemidoc Touch Imaging System.

**Colony formation assay (CFA)**

Cells were seeded and transfected with 50 nM RIF1 siRNA using Lipofectamine RNAimax (Invitrogen) together with Optimem (Gibco) in the case of HEK293-based cell lines. For HCT116-based cell lines, cells were seeded with 0.2 μg/ml DOX. After two days, cells were counted using the Invitrogen Countess II FL Automated Cell Counter and 250 cells added to each well of a 6-well plate. For HEK293-based cell lines, 1 μg/ml DOX was added to the culture medium to induce ectopic RIF1 expression whilst for HCT116-derived cell lines, 10 μM Auxin was added to the culture medium to degrade RIF1. Cells were incubated for 24 hr after which Aphidicolin was added and cells incubated for a further 24 hr, before washing twice with PBS and replacement with the appropriate Aphidicolin-free medium. For HEK293-derived cell lines, 1 μg/ml supplementary DOX was re-added 72 hr after Aphidicolin removal and cells were then incubated for a further 4 days. In the case of

HCT116-derived cell lines, after Aphidicolin removal, cells were incubated for 7 days. At the end of the incubation period, colonies consisting of more than 20 cells were counted using a Nikon Eclipse TS100 microscope.

**Flow cytometry**

To assess DNA content, cells were recovered by trypsinisation, then fixed with 70% ethanol. Cells were spun down and resuspended in 0.5 ml FxCyclePI/RNase staining solution (Molecular Probes, F10797) and incubated for 30 minutes at room temperature, protected from light. DNA content was analysed on a Becton Dickinson Fortessa analytical flow cytometer, and cell cycle distribution measured using FlowJo software. Doublet discrimination was performed by gating FSC-A against FSC-H.

To measure the mClover fluorescence of the mAC-RIF1 fusion protein, cells were recovered by trypsinsation and fixed with a 10% neutral buffered formalin solution (Sigma, HT-5012) for 30 minutes at 4°C, protected from light. Cells were washed with PBS/1% BSA before analysis on a Becton Dickinson Fortessa. mAC-RIF1 signal was measured using FlowJo software. Doublet discrimination was performed by gating FSC-A against FSC-H. An equal number of events are shown in each set of histogram plots.

**Cell cycle synchronisation**

HCT116 cells were seeded in 12-well dishes and treated with 20 μM Lovastatin for 24 hr to induce G1 arrest[41]. Cells were washed and medium containing 2 mM Mevalonic acid (MVA) added to induce release. 8 hr after release, 9 μM RO-3306 was added to hold cells at the G2/M boundary[42,43]. After 28 hr, cells were washed and drug-free medium added allowing cells to enter mitosis. Flow cytometry was used to analyse synchronisation efficiency, and to establish and optimise the procedure for the experiment in Figure 3 based on assessment of cell cycle progression kinetics.

**DNA fiber assay**

Cells were pulse-labeled with 50 μM CldU (20 min), followed by another pulse of 20 min of 250 μM IdU. After treatment with hydroxyurea (HU) 2 mM for 4 hours, cells were harvested and lysed on a microscope slide with spreading buffer (200 mM Tris pH 7.4, 50 mM EDTA, 0.5% SDS). Slides were tilted to allow the DNA suspension to run slowly and spread the fibers down the slide. Slides were fixed in cold (-20 ºC) methanol-acetic acid (3:1) and DNA

denatured in 2.5 M HCl at RT for 30 min. Slides were blocked and incubated with the following primary antibodies for 1 hour at RT in humidity chamber (anti-CldU, Abcam ab6326, 1:100; anti-IdU, BD 347580, 1:100; anti-ssDNA, Millipore MAB3034, 1:100). After washes with PBS, the slides were incubated with the following secondary antibodies (anti-rat IgG Alexa Fluor 594, Molecular Probes A-11007; anti-mouse IgG1 Alexa Fluor 488, Molecular Probes A-21121; anti-mouse IgG2a Alexa Fluor 350, Molecular Probes A-21130). Slides were air-dried and mounted with Prolong (Invitrogen). Samples were imaged under a Zeiss Axio Imager and analysed using ImageJ. CldU and IdU tract lengths were measured in double-labelled forks and the IdU/CldU ratio was used as an indicator of nascent DNA degradation.

**Live cell imaging**

Live cell imaging was performed using a DeltaVision microscope equipped with an incubation chamber and a $CO_2$ supply (GE healthcare Life Sciences). HCT116 cells were cultured in a glass-bottomed dish (MatTek) containing the medium without phenol red at 37 ºC with 5% $CO_2$. To visualize nuclei in live cells, 0.5 µM SiR-DNA (Spirochrome) was added to the medium before observation. Image analysis and quantification were performed using the Volocity software (PerkinElmer). The half-life of mClover signal was calculated using the Prism software (GraphPad).

**Confocal microscopy**

HCT116 cells were cultured in ibiTreat µ-slide 8 well dishes (Ibidi) at 37 ºC with 5% $CO_2$. Cells were treated with 1 µM Aphidicolin for 24 hr after which Aphidicolin was removed and cells were incubated for a further 12 hr. Cells were fixed with either a 10% neutral buffered formalin solution (Sigma, HT-5012) for 10 minutes at room temperature or with 100% methanol for 15 minutes at -20 ºC. Blocking was for 30 minutes with PBST/1%BSA at 4 ºC after which antibody staining was performed. Confocal microscopy was performed using an LSM880 + Airyscan (Zeiss). x63 magnification was used and Z-stacks were imaged (40 slices). Images were processed first to an airyscan image and then to a maximum intensity projection (MIP) using ZEN Black (Zeiss). Image analysis and quantification was performed using CellProfiler (Broad Institute) and statistics were calculated using Prism (Graphpad).

**List of antibodies used in this study**

The following antibodies were used for western blotting:

- RIF1; Bethyl Laboratories; A300-568A; Rabbit polyclonal
- MCM4; Abcam; ab4459; Rabbit polyclonal
- GFP; Abcam; ab290; Rabbit polyclonal
- Tubulin; Santa Cruz Biotechnology; sc-53030; Rat monoclonal

The following antibodies were used for microscopy analysis:

- 53BP1; Santa Cruz Biotechnology; sc-22760; Rabbit polyclonal
- FANCD2; Novus Biologicals; NB100-182; Rabbit polyclonal
- BLM; Santa Cruz Biotechnology; sc-7790; Goat polyclonal
- Anti-rabbit Alexa Fluor 594; Thermo Fisher Scientific; A-11037
- Anti-goat Alexa Fluor 594; Thermo Fisher Scientific; A-11058
- GFP-Booster ATTO 488; ChromoTek; gba488
- Cyclin A2 (Alexa Fluor 555); Abcam; ab217731; rabbit monoclonal
- 53BP1; Novus Biologicals; NB100-94, rabbit polyclonal – self conjugated to Lighting-Link Rapid Alexa Fluor 647, Expedeon, 336-0030

**Acknowledgements**

Thanks to members of the Aberdeen Chromosome Stability Group for discussion. We are grateful to Kevin Hiom for thoughtful comments on the manuscript. We thank Raif Yuecel and his team at the University of Aberdeen Iain Fraser Cytometry Centre for assistance, and Kevin McKenzie and his team at the University of Aberdeen Microscopy and Histology Core Facility for microscopy support. Work at the University of Aberdeen was supported by Cancer Research UK Studentship Award C1445/A20596 and CRUK Programme Award C1445/A19059. Work at the National Institute of Genetics, Mishima was supported by JSPS KAKENHI Grants Numbers 17K15068, 18H02170 and 18H04719, and by research grants from the Daiichi Snakyo Foundation of Life Science, and the Takeda Science Foundation. Collaboration between the two groups was supported by NIG-JOINT (98I2019). LW was supported by a 2017 JSPS Summer Programme Fellowship.

**Author Contributions**

LPW, SH, TN, MK and ADD conceived and designed the experiments. LPW, SH, TN, YS, JG and MK performed experiments. LPW, SH and TN analysed the data. LPW, SH and ADD wrote the manuscript.

**Conflict of interest**

Authors declare no conflict of interest.

**References**


1. Escribano-Díaz, C. *et al.* A Cell Cycle-Dependent Regulatory Circuit Composed of 53BP1-RIF1 and BRCA1-CtIP Controls DNA Repair Pathway Choice. *Mol. Cell* **49**, 872–883 (2013).
2. Chapman, J. R. *et al.* RIF1 Is Essential for 53BP1-Dependent Nonhomologous End Joining and Suppression of DNA Double-Strand Break Resection. *Mol. Cell* **49**, 858–871 (2013).
3. Hiraga, S. *et al.* Human RIF 1 and protein phosphatase 1 stimulate DNA replication origin licensing but suppress origin activation. *EMBO Rep.* **18**, 403–419 (2017).
4. Virgilio, M. Di *et al.* Rif1 Prevents Resection of DNA Breaks and Promotes Immunoglobulin Class Switching. *Science* **339**, 711–715 (2013).
5. Bunting, S. F. *et al.* 53BP1 inhibits homologous recombination in brca1-deficient cells by blocking resection of DNA breaks. *Cell* **141**, 243–254 (2010).
6. Setiaputra, D. & Durocher, D. Shieldin – the protector of DNA ends. *EMBO Rep.* **20**, e47560 (2019).
7. Mazouzi, A. *et al.* A Comprehensive Analysis of the Dynamic Response to Aphidicolin-Mediated Replication Stress Uncovers Targets for ATM and ATMIN. *Cell Rep.* **15**, 893–908 (2016).
8. Buonomo, S. B. C., Wu, Y., Ferguson, D. & De Lange, T. Mammalian Rif1 contributes to replication stress survival and homology-directed repair. *J. Cell Biol.* **187**, 385–398 (2009).
9. Kumar, R. & Cheok, C. F. RIF1: A novel regulatory factor for DNA replication and DNA damage response signaling. *DNA Repair (Amst).* **15**, 54–59 (2014).
10. Syvaoja, J. *et al.* DNA polymerases α, δ, and ε: Three distinct enzymes from HeLa cells. *Proc. Natl. Acad. Sci.* **87**, 6664–6668 (1990).
11. Ogi, T. *et al.* Identification of the First ATRIP-Deficient Patient and Novel Mutations

in ATR Define a Clinical Spectrum for ATR-ATRIP Seckel Syndrome. *PLoS Genet.* **8**, e1002945 (2012).

12. Kerzendorfer, C., Colnaghi, R., Abramowicz, I., Carpenter, G. & O'Driscoll, M. Meier-Gorlin syndrome and Wolf-Hirschhorn syndrome: Two developmental disorders highlighting the importance of efficient DNA replication for normal development and neurogenesis. *DNA Repair (Amst).* **12**, 637–644 (2013).
13. Burrell, R. A. *et al.* Replication stress links structural and numerical cancer chromosomal instability. *Nature* **494**, 492–496 (2015).
14. Feng, D., Tu, Z., Wu, W. & Liang, C. Inhibiting the Expression of DNA Replication-Initiation Proteins Induces Apoptosis in Human Cancer Cells 1. *Cancer Res.* **63**, 7356–7364 (2003).
15. Imai, R. *et al.* Chromatin folding and DNA replication inhibition mediated by a highly antitumor-active tetrazolato-bridged dinuclear platinum(II) complex. *Sci. Rep.* **6**, 24712 (2016).
16. Peti, W., Nairn, A. C. & Page, R. Structural basis for protein phosphatase 1 regulation and specificity. *FEBS J.* **280**, 596–611 (2013).
17. Davé, A., Cooley, C., Garg, M. & Bianchi, A. Protein Phosphatase 1 Recruitment by Rif1 Regulates DNA Replication Origin Firing by Counteracting DDK Activity. *Cell Rep.* **7**, 53–61 (2014).
18. Hiraga, S. I. *et al.* Rif1 controls DNA replication by directing Protein Phosphatase 1 to reverse Cdc7- mediated phosphorylation of the MCM complex. *Genes Dev.* **28**, 372–383 (2014).
19. Mattarocci, S. *et al.* Rif1 Controls DNA replication timing in yeast through the PP1 Phosphatase Glc7. *Cell Rep.* **7**, 62–69 (2014).
20. Alver, R. C., Chadha, G. S., Gillespie, P. J. & Blow, J. J. Reversal of DDK-Mediated MCM Phosphorylation by Rif1-PP1 Regulates Replication Initiation and Replisome Stability Independently of ATR/Chk1. *Cell Rep.* **18**, 2508–2520 (2017).
21. Garzón, J., Ursich, S., Lopes, M., Hiraga, S. ichiro & Donaldson, A. D. Human RIF1-Protein Phosphatase 1 Prevents Degradation and Breakage of Nascent DNA on Replication Stalling. *Cell Rep.* **27**, 2558–2566 (2019).
22. Chaudhuri, A. R. *et al.* Replication fork stability confers chemoresistance in BRCA-deficient cells. *Nature* **538**, 382–389 (2016).
23. Hengeveld, R. C. C. *et al.* Rif1 Is Required for Resolution of Ultrafine DNA Bridges in Anaphase to Ensure Genomic Stability. *Dev. Cell* **34**, 466–474 (2015).

24. Bergoglio, V. *et al.* DNA synthesis by Pol eta promotes fragile site stability by preventing under-replicated DNA in mitosis. *J Cell Biol.* **201**, 395–408 (2013).
25. Bhowmick, R., Minocherhomji, S. & Hickson, I. D. RAD52 Facilitates Mitotic DNA Synthesis Following Replication Stress. *Mol. Cell* **64**, 1117–1126 (2016).
26. Bruhn, C., Zhou, Z. W., Ai, H. & Wang, Z. Q. The essential function of the MRN complex in the resolution of endogenous replication intermediates. *Cell Rep.* **6**, 182–195 (2014).
27. Lukas, C. *et al.* 53BP1 nuclear bodies form around DNA lesions generated by mitotic transmission of chromosomes under replication stress. *Nat. Cell Biol.* **13**, 243–253 (2011).
28. Moreno, A. *et al.* Unreplicated DNA remaining from unperturbed S phases passes through mitosis for resolution in daughter cells. *Proc. Natl. Acad. Sci.* **113**, E5757–E5764 (2016).
29. Bhowmick, R. *et al.* The RIF1-PP1 Axis Controls Abscission Timing in Human Cells. *Curr. Biol.* **29**, 1232-1242.e5 (2019).
30. Xu, L. & Blackburn, E. H. Human Rif1 protein binds aberrant telomeres and aligns along anaphase midzone microtubules. *J. Cell Biol.* **167**, 819–830 (2004).
31. Xu, D. *et al.* Rif1 provides a new DNA-binding interface for the Bloom syndrome complex to maintain normal replication. *EMBO J.* **29**, 3140–3155 (2010).
32. Batenburg, N. L. *et al.* ATM and CDK2 control chromatin remodeler CSB to inhibit RIF1 in DSB repair pathway choice. *Nat. Commun.* **8**, 1921 (2017).
33. Natsume, T., Kiyomitsu, T., Saga, Y. & Kanemaki, M. T. Rapid Protein Depletion in Human Cells by Auxin- Inducible Degron Tagging with Short Homology Resource Rapid Protein Depletion in Human Cells by Auxin-Inducible Degron Tagging with Short Homology Donors. *Cell Rep.* **15**, 210–218 (2016).
34. Nishimura, K., Fukagawa, T., Takisawa, H., Kakimoto, T. & Kanemaki, M. T. An auxin-based degron system for the rapid depletion of proteins in nonplant cells. *Nat. Methods* **6**, 917–923 (2009).
35. Lam, A. J. *et al.* Improving FRET dynamic range with bright green and red fluorescent proteins. *Nat. Methods* **9**, 1005–1012 (2012).
36. Yesbolatova, A., Natsume, T., Hayashi, K. ichiro & Kanemaki, M. T. Generation of conditional auxin-inducible degron (AID) cells and tight control of degron-fused proteins using the degradation inhibitor auxinole. *Methods* (2019). doi:10.1016/j.ymeth.2019.04.010

37. Yamazaki, S. *et al.* Rif1 regulates the replication timing domains on the human genome. *EMBO J.* **31**, 3667–77 (2012).
38. Magidson, V. *et al.* Adaptive changes in the kinetochore architecture facilitate proper spindle assembly. *Nat. Cell Biol.* **17**, 1134–1144 (2015).
39. Chan, K. L., North, P. S. & Hickson, I. D. BLM is required for faithful chromosome segregation and its localization defines a class of ultrafine anaphase bridges. *EMBO J.* **26**, 3397–3409 (2007).
40. Barefield, C. & Karlseder, J. The BLM helicase contributes to telomere maintenance through processing of late-replicating intermediate structures. *Nucleic Acids Res.* **40**, 7358–7367 (2012).
41. Rao, S. *et al.* Lovastatin-mediated G 1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. *Biochemistry* **96**, 7797–7802 (1999).
42. Moghadam-Kamrani, S. J. & Keyomarsi, K. Synchronization of the cell cycle using lovastatin. *Cell Cycle* **7**, 2434–2440 (2008).
43. Vassilev, L. T. *et al.* Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. *Proc. Natl. Acad. Sci. U. S. A.* **103**, 10660–5 (2006).
44. Kedziora, S. *et al.* Rif1 acts through Protein Phosphatase 1 but independent of replication timing to suppress telomere extension in budding yeast. *Nucleic Acids Res.* **46**, 3993–4003 (2018).
45. Kilic, S. *et al.* Phase separation of 53 BP 1 determines liquid-like behavior of DNA repair compartments. *EMBO J.* 1–17 (2019). doi:10.15252/embj.2018101379
46. Spies, J. *et al.* 53BP1 nuclear bodies enforce replication timing at under-replicated DNA to limit heritable DNA damage. *Nat. Cell Biol.* **21**, 487–497 (2019).
47. Yusa, K., Zhou, L., Li, M. A., Bradley, A. & Craig, N. L. A hyperactive piggyBac transposase for mammalian applications. *Proc. Natl. Acad. Sci.* **108**, 1531–1536 (2011).
48. O'Gorman, S., Fox, D. T. & Wahl, G. M. Recombinase-mediated gene activation and site-specific integration in mammalian cells. *Science* **251**, 1351–1355 (1991).
49. Hayashi, K. *et al.* Rational Design of an Auxin Antagonist of the SCF. *ACS Chem. Biol.* **7**, 590–598 (2012).
50. Le Cong, F. *et al.* Multiplex Genome Engineering using CRISPR/Cas System. *Science* **339**, 819–823 (2013).
51. Ran, F. A. *et al.* Genome engineering using the CRISPR-Cas9 system. *Nat. Protoc.* **8**,

2281–2308 (2013).
52. Mailand, N. & Diffley, J. F. X. CDKs promote DNA replication origin licensing in human cells by protecting Cdc6 from APC/C-dependent proteolysis. *Cell* **122**, 915–926 (2005).

**Figure legends**

**Figure 1: Cells lacking RIF1 are sensitive to replicative stress**

**(A)** Confirmation of siRIF1 efficacy by western blotting. Three days after siRNA transfection, whole cell protein extracts were analysed by western blotting with anti-RIF1 antibody. Loading control shows Ponceau S staining. **(B)** Colony Formation Analysis (CFA) of HEK293 cells treated with siRIF1. ***$p<0.001$ **(C)** CFA comparing Aphidicolin sensitivity of $RIF1^{+/+}$ and $RIF1^{-/-}$ MEF cells. *$p<0.05$. **(D)** CFA comparing Aphidicolin sensitivity of HCT116 mAC-RIF1 and HCT116 RIF1-KO cells. ****$p<0.0001$. In each case values were normalized to the DMSO control, and plots show averages and standard deviations of technical triplicates.

**Figure 2: Characterisation of HCT116-based cell lines with Auxin Inducible Degron-tagged RIF1**

**(A)** Structure of Auxin Inducible Degron (AID)-tagged RIF1 construct (mAC-RIF1), located at both the endogenous RIF1 loci on chromosome 2 in HCT116 cells carrying the auxin-responsive F-box protein *Oryza sativa* TIR1 (OsTIR1) under DOX control. The RIF1 gene is fused to a tag containing a self-cleaving hygromycin resistance marker, mini-Auxin Inducible Degron (mAID) and monomer Clover (mClover) protein. **(B)** Confirmation of mAC-RIF1 protein degradation. Cells were incubated with 2 μg/ml DOX and 500 μM Auxin for 24 hr, then protein extracts analysed by western blotting. **(C)** mAC-RIF1 degradation assessed by microscopy. mAC-RIF1 cells were treated with 2 μg/ml DOX and 500 μM Auxin for 24 hr. DNA was stained with SiR-DNA. Scale bar = 10 μm. **(D)** Examples of mAC-RIF1 localisation at different cell cycle stages. DNA was stained with SiR-DNA, and imaging performed using a Deltavision microscope.

**Figure 3: RIF1 is essential during and after drug treatment to protect against effects of replication stress**

**(A)** CFA testing Aphidicolin sensitivity of HCT116 mAC-RIF1 cells depleted for RIF1. Cells were treated with DOX and 500 μM Auxin for 48 hr before seeding at low density and treatment with Aphidicolin concentrations indicated. 'No Auxin' cells were treated with DOX and Auxinole. Values normalized to 0 μM APH (DMSO) control. Average values and standard deviations of technical triplicates are shown. *p<0.05; **p<0.01; ***p<0.001 **(B)** Procedure for testing effect of depleting RIF1 in synchronised cultures during or after Aphidicolin treatment. HCT116 mAC-RIF1 cells were incubated with Lovastatin to arrest cells in G1. After 24 hr, cells were released from G1 arrest with Mevalonic Acid. 4 hr into release (28 hr), RIF1 depletion was induced in 'condition I' cells by addition of DOX and Auxin. 8 hr into release (32 hr), 1 μM Aphidicolin was added (to both cultures) to induce replication stress and simultaneously, RO-3306 was added to arrest cells in G2 phase. 24 hr later (at 56 hr), in 'condition I' cells RIF1 was re-expressed by removal of DOX and Auxin and addition of Auxinole. Also at 56 hr, in 'condition II' cells RIF1 depletion was induced by addition of DOX and Auxin. 4 hr later (60 hr), both cell cultures were released from RO-3306. After 4 hr (64 hr), cells were seeded at 250/well in 6-well plates, then incubated for 7 days after which colonies were counted. **(C)** Cell cycle progression in HCT116 mAC-RIF1 cells during the procedure shown in B. Synchronisation was performed as in B in the presence of 1 μM Aphidicolin. Flow cytometry analysis was performed on a BD LSR Fortessa. The histograms show distribution of cellular DNA content at the time indicated. **(D)** Effect on colony formation rates of mAC-RIF1 depletion procedures combined with 1 μM Aphidicolin treatment, 'condition I' and 'condition II' cells treated according to the procedure shown in B. RIF1+ and RIF1- correspond to control mAC-RIF1 cells in which RIF1 was either expressed or depleted throughout the procedure. Values shown are normalised to the RIF1+ control. Average values and standard deviations of technical triplicates are shown. ***p<0.001.

**Figure 4: RIF1-L promotes resistance to Aphidicolin treatment but RIF1-S cannot**
**(A)** Illustration of HCT116 mAC-RIF1-L and mAC-RIF1-S cell lines. By CRISPR mediated integration of donor plasmids into HCT116 mAC-RIF1 cell line, the RIF1 cDNA of the C-terminal portion of RIF1 was inserted at the end of exon 29. **(B)** Expression of RIF1 in HCT116 mAC-RIF1, mAC-RIF1-L, mAC-RIF1-S and RIF1 KO cell lines. Whole cell extracts were harvested for western blotting with anti-RIF1 antibody. Loading control shows Ponceau S staining. **(C)** CFA comparing resistance of mAC-RIF1(black bars), mAC-RIF1-L

(red bars) mAC-RIF1-S (grey bars), and RIF1-KO (open bars) cell lines to treatment with different Aphidicolin concentrations. Values normalised to the DMSO control. Average values and standard deviations of technical triplicates are shown. *p<0.05; **p<0.01; ****p<0.0001. **(D)** CFA comparing effects of HEK293 GFP-RIF1-L (red bars) and GFP-RIF1-S (grey bars) expression on Aphidicolin resistance. Experiment was carried out as in S4C, with Aphidicolin treatment at concentrations indicated. Values were normalised to the no Aphidicolin (DMSO) control. Average values and standard deviations of technical triplicates are shown. **p<0.01; ***p<0.001; ****p<0.0001; *****p<0.00001. **(E)** Both HEK293 GFP-RIF1-L and GFP-RIF1-S can counteract MCM4 hyperphosphorylation caused by depletion of endogenous RIF1. 24 hr after transfection with either siControl or siRIF1, DOX was added to the culture medium. 24 hr later, chromatin-enriched protein fractions were prepared and analysed by western blotting with anti-MCM4 antibody. Hyperphosphorylated MCM4 protein (MCM4-P) shows retarded mobility as indicated by bracket. **(F)** DNA fiber assay. HEK293-derived cell lines were transfected with siCon or siRIF1 to deplete endogenous RIF1. The following day, expression of the stably integrated GFP, GFP-RIF1-L and GFP-RIF1-S was induced by addition of doxycycline (DOX). 2 days later cells were labeled with CldU and IdU, followed by a treatment with hydroxyurea (HU) 2 mM for 4 hours. DNA fiber assay was performed to assess nascent DNA degradation. Bar in the graph represents median value. 75 forks were analysed per sample and statistical significance was calculated using a Mann-Whitney test. NS; not significant; **** $p \leq 0.0001$.

**Figure 5: RIF1-L preferentially localises to 53BP1 protective nuclear bodies and promotes their formation**

**(A)** Representative images showing 53BP1 nuclear bodies and RIF1 foci in HCT116 cell lines. Cells were treated with 1 μM Aphidicolin for 24 hr then released for 12 hr before fixing. Confocal microscopy was performed using an LSM880 + Airyscan (Zeiss). Scale bar = 2 μm. **(B)** Number of cells with 4 or more 53BP1 nuclear bodies in cells either untreated or treated with APH as in A. Plot shows averages and standard deviations from three experiments. NS; not significant, *p<0.05; ***p<0.001; ****p<0.0001. **(C)** Number of 53BP1 nuclear bodies colocalised with RIF1 foci per cells in untreated and APH-treated HCT116 cells. Averages and standard deviations taken from three independent experiments are shown. ****p<0.0001. **(D)** Illustration of RIF1-L and -S isoform functions.

**Supplementary Figure 1: Characterisation and optimisation of mAC-RIF1 depletion**
**(A)** Optimisation of DOX concentration for TIR1 induction in HCT116 mAC-RIF1 cell line. Cells were treated with a range of DOX concentrations as indicated and mClover signal was analysed by flow cytometry, establishing that 0.2 μg/ml DOX is sufficient for degradation. **(B)** Optimisation of Auxin for SCF-OsTIR1-mediated RIF1 depletion in HCT116 mAC-RIF1 cell line. Cells were treated with a range of Auxin concentrations as indicated and mClover signal was analysed by flow cytometry, establishing that 10 μM Auxin is sufficient for degradation. **(C)** mAC-RIF1 depletion analysed by flow cytometry. Cells were treated with 2 μg/ml DOX and Auxinole (to suppress reduction in mAC-RIF1 flourescence signal from OsTIR1 induction by treatment with DOX alone) for 24 hr (plot 4 from top), then medium was replaced with 2 μg/ml DOX and 500 μM Auxin for the indicated time periods (plots 5-8). Plots 1-3 show mClover signal in Untagged cells and in cells treated with No drug or DOX only. Samples were taken at the indicated time points and mClover signal analysed by flow cyometry. mAC-RIF1 depletion was largely complete after 3 hr of Auxin treatment, as assessed by comparison with a DOX + Auxin 24 hr sample (seventh and eighth plots).
**(D)** Testing re-expression of mAC-RIF1 following a period of depletion. RIF1 was first depleted by adding DOX and Auxin for 24 hr. Cells were washed three times after which Auxinole-containing medium was added. Samples were taken at the indicated time points and mClover signal analysed by flow cytometry. Based on the kinetics of RIF1 depletion and re-expression, a 4 hr window was allowed for complete depletion or re-expression of RIF1.

**Supplementary Figure 2: Cellular localisation of mClover-tagged RIF1**
**(A)** mAC-RIF1 co-localises with BLM at UFBs but not with 53BP1 or FANCD2 repair proteins. **(B)** Montage showing stills from time-lapse imaging of mAC-RIF1 and mCherry-PCNA in HCT116 cell progressing from early to late S phase. Scale bars = 10 μm (see Video 1). Bright mAC-RIF1 foci intensified as the cells progressed through S phase. **(C)** Montage showing stills from time-lapse imaging of mAC-RIF1 and mCherry-PCNA in HCT116 cell progressing from late S phase to the following G1 phase. mAC-RIF1 foci disappear by metaphase (180-210 min) and reappear on telophase chromosomes and anaphase bridges (220-230 min). Scale bars = 10 μm (see Video 2).

**Supplementary Figure 3: RIF1 is needed both during and after drug treatment to protect cells from replication stress, in synchronised and unsynchronised cultures**

**(A)** Synchronisation of HCT116 mAC-RIF1 cells. Cells were arrested at G1 phase with Lovastatin for 24 hr ('G1 arrest') then released with Mevalonic acid (no Aphidicolin). After 8 hr, RO-3306 was added to arrest cells in G2 phase. 19 hr later ('G2 arrest'), cells were released by washing out the RO-3306, and sampled 4 hr later. Samples were taken at the indicated points through the experiment and DNA stained with PI prior to flow cytometry analysis. **(B)** Effect on colony formation rates of mAC-RIF1 depletion during or after 1 μM Aphidicolin treatment, treated according to 'condition I' or 'condition II' procedures shown in Fig. 4B. RIF1+ and RIF1- correspond to control mAC-RIF1 cells with RIF1 either expressed or depleted throughout the experiment. Experiment represents a duplicate of that in Fig. 4D. Values were normalised to the RIF1+ condition. The experiment was performed in technical triplicates. *$p<0.05$; ***$p<0.001$; ****$p<0.0001$ **(C)** Outline of procedure for testing effect of RIF1 depletion either during or after Aphidicolin treatment, in unsynchonised cultures. Cells were seeded at 250 cells/well in 6-well plates in the presence of DOX and Auxinole. On day 2, Aphidicolin was added, and then removed on day 3. Cells were incubated for 7 days after which colonies were counted using a Nikon Eclipse TS100 microscope. For condition III (treatment RIF1- / recovery RIF1+), RIF1 was depleted during the drug treatment period, with DOX and Auxin added to the medium 3 hr before Aphidicolin was added. 3 hr before the end of the drug treatment, RIF1 was re-expressed by replacing medium with medium containing Auxinole. For condition IV (treatment RIF1+ / recovery RIF1-), DOX and Auxinole were maintained in the medium until 3 hr before the end of the drug treatment when it was replaced with medium containing DOX and Auxin to induce RIF1 depletion. **(D)** Results of experiment in Fig. S3C testing whether RIF1 is needed during or after drug treatment to protect cells from replication stress. HCT116 mAC-RIF1 cells were depleted of RIF1 either during the 24 hr Aphidicolin treatment (condition III, horizonal lined bars) or during the recovery period (condition IV, hatch pattern bars). For the 'RIF1-' condition (open bars), RIF1 was depleted by DOX and Auxin addition 24 hr before drug treatment. Values were normalised to the no drug control. Average values and standard deviations of technical triplicates are shown. *$p<0.05$; **$p<0.01$; ***$p<0.001$ **(E)** Duplicate experiment of that shown in part C & D, except that a window of 4 hr was used for depletion and re-expression of RIF1. That is, for condition III DOX and Auxin added to the medium 4 hr before Aphidicolin was addition, then replaced with Auxinole medium 4 hr before the removal of Aphidicolin; while for condition IV medium contained DOX and Auxinole until 4 hr before the end of the drug treatment, then replaced with medium containing DOX and

Auxin. Values were normalised to the no drug control. Average values and standard deviations of technical triplicates are shown. *p<0.05; **p<0.01; ***p<0.001.

**Supplementary Figure 4: HEK293 RIF1-L and RIF1-S ectopic expression system**

**(A)** Illustration of DOX-controlled GFP-RIF1-L and GFP-RIF1-S cDNA constructs. Following siRNA-mediated depletion of endogenous RIF1, splice variant-specific expression of RIF1 is induced by the addition of 1 μg/ml DOX. **(B)** Expression of endogenous RIF1, or GFP-RIF1-L and GFP-RIF1-S, in cells treated with siControl or siRIF1. DOX was added to the culture medium 24 hr before whole cell extracts were harvested for western blotting. The same protein samples are shown probed with anti-RIF1 (top), anti-GFP (middle), or loading control anti-tubulin (bottom). **(C)** Modified CFA assay. On Day 1, GFP-RIF1-L and GFP-RIF1-S cells were transfected with siRIF1 or non-targeting control siRNA. On day 3, cells were seeded with DOX to induce transcription of siRNA-resistant GFP-RIF1-L or GFP-RIF1-S constructs. On day 4, Aphidicolin was added then removed on day 5. Cells were incubated for a further 7 days then colonies counted on day 12.

**Supplementary Figure 5: RIF1-L resistance to Aphidicolin treatment is largely independent of PP1 interaction**

**(A)** Illustration of RIF1 PP1-interaction motifs. To prevent PP1 interaction, critical residues in all three potential PP1 interaction motifs were replaced with alanine, creating a RIF1-pp1bs allele. **(B)** Expression of GFP-RIF1-pp1bs in HEK293 Flp-In T-Rex cells. 48 hr after transfection with siRIF1, DOX was added to the culture medium. After 24 hr, expression was assessed by western blotting with anti-RIF1 antibody. **(C)** CFA comparing effect of GFP-RIF1-L and GFP-RIF1-L-pp1bs expression on Aphidicolin resistance. The CFA was carried out as in Fig. 4C. Values were normalised to the no drug control. Average values and standard deviations of technical triplicates are shown. **p<0.01.

**Supplementary Figure 6: Distribution of 53BP1 nuclear bodies after Aphidicolin treatment**

**(A)** Distribution of the number of 53BP1 nuclear bodies per cell as a % of the cell population in untreated and treated HCT116 cells, from same cultures as in Figure 5A. Average values and standard deviations from three independent experiments are shown.

**mClover-tagged RIF1 time-lapse imaging**

**(Video 1)** Time-lapse imaging video of unsynchronised HCT116 mAC-RIF1 mCherry-PCNA cells transitioning from early to late S phase. **(Video 2)** Time-lapse imaging video of unsynchronised HCT116 mAC-RIF1 mCherry-PCNA cells transitioning from late S to the following G1 phase.


A
HEK293
siCon
siRIF1
RIF1
Ponceau
B
HEK293
siCon
siRIF1
Relative CFU
1.5
1.0
0.5
0.0
***
0
0.6
Aphidicolin (μM)
C
MEF
RIF1 +/+
RIF1 -/-
Relative CFU
1.5
1.0
0.5
0.0
*
0
0.6
Aphidicolin (μM)
D
HCT116
mAC-RIF1
RIF1 KO
Relative CFU
1.5
1.0
0.5
0.0
****
0
0.6
Aphidicolin (μM)


A
Structure of mAC-RIF1 gene
(chromosome 2)
P2A
Hygro
mAID
Clover
Exon 1
Exon 35 (last)
B
Untagged
mAC-RIF1
DOX/Auxin(24h)
-
+
-
+
RIF1
mAC-RIF1
RIF1
Ponceau
C
DNA
mAC-RIF1
DNA
mAC-RIF1
+ DOX
+ DOX
+ Auxin
(projection)


D
DNA
mAC-RIF1
DNA
mAC-RIF1
S phase
Prometaphase
Anaphase
Telophase
(projection)


A
mAC-RIF1
no auxin
+ auxin
Relative CFU
1.5
1.0
0.5
0.0
***
*
**
0
0.3
0.6
1
Aphidicolin (μM)
B
Lovastatin
(G1 arrest)
Aphidicolin
+
RO-3306 (G2 arrest)
0
24
32
60
64 (hr)
G1
S
G2/M
Plate
cells
Count
colonies
7 days
I No RIF1 during
replication stress
28
56
+Auxin
(RIF1 depleted)
II No RIF1 after
replication stress
56
+Auxin
(RIF1 depleted)
C
mAC-RIF1
Time (hr)
0
24
47
60
DNA content
D
Relative CFU
1.5
1.0
0.5
0.0
***
***
***
RIF1+
RIF1-
I
II


A
Chromosome 2
mAC-RIF1
1
31
mAC
mAC-RIF1-L
cDNA
N
mAC-RIF1-S
cDNA
N
B
maC-RIF1
maC-RIF1-L
maC-RIF1-S
RIF1 KO
RIF1
Ponceau
C
Relative CFU
1.5
1.0
0.5
0.0
0
0.3
0.6
1
Aphidicolin (μM)
mAC-RIF1
mAC-RIF1-L
mAC-RIF1-S
RIF1 KO
D
Relative CFU
1.5
1.0
0.5
0.0
0
0.3
0.6
1
Aphidicolin (μM)
GFP-RIF1-L + DOX
GFP-RIF1-S + DOX
GFP-RIF1-L - DOX
GFP-RIF1-S - DOX
E
siRIF1
siCon
GFP
GFP
GFP-RIF1-S
GFP-RIF1-L
DOX
+
+
+
+
MCM4-P
MCM4
Ponceau
F
IdU/CldU Ratio
2.0
1.5
1.0
0.5
0.0
****
****
****
NS
GFP (siCon)
GFP (siRIF1)
GFP-RIF1-L
GFP-RIF1-S

Watts_Fig5


A
DNA
mAC-RIF1
53BP1
Merge
mAC-RIF1
mAC-RIF1-L
mAC-RIF1-S
RIF1 KO


B
% cells with ≥ 4 53BP1 bodies
30
20
10
0
***
***
NS
***
*
No Aphidicolin
+Aphidicolin
mAC-RIF1
mAC-RIF1-L
mAC-RIF1-S
RIF1 KO


C
Number of 53BP1 bodies colocalised with RIF1/ cell
1.5
1.0
0.5
0.0
****
****
No Aphidicolin
+Aphidicolin
mAC-RIF1
mAC-RIF1-L
mAC-RIF1-S


D
Origin repression
PP1
RIF1-L/S
Nascent DNA protection
S
G1
G2
M
Promotes 53BP1 bodies after replication stress
RIF1-L


A
mAC-RIF1
+ Auxinole
+ Auxin
DOX
0.2 µg/ml
0.5 µg/ml
1 µg/ml
2 µg/ml
Clover signal
B
mAC-RIF1
DOX + Auxin
Auxin
10 µM
100 µM
200 µM
300 µM
500 µM
Clover signal
C
mAC-RIF1
Untagged
No DOX
DOX
DOX + Auxinole
DOX + Auxin
1 hr
2 hr
3 hr
24 hr
Clover signal
D
mAC-RIF1
DOX + Auxinole
Dox + Auxin
Re-express
+ Auxinole
5 hr
7 hr
9 hr
24 hr
Clover signal

Watts_SupFig2




A
mAC-RIF1
AS
G1 arrest
G2 arrest
4 hr after release from RO-3306
DNA Content


B
Relative CFU
1.5
1.0
0.5
0.0
***
***
****
*
RIF1+
RIF1-
I
II


C
Seed cells at low density
Aphidicolin
Count colonies
Day
1
2
3
7 days
III treatment RIF1- /recovery RIF1 +
+Auxin
IV treatment RIF1+ /recovery RIF1 -
+Auxin


D
Relative CFU
1.5
1.0
0.5
0.0
**
***
*
0
0.3
0.6
1
Aphidicolin (μM)
RIF1+
RIF1-
III
IV


E
Relative CFU
1.5
1.0
0.5
0.0
0
0.3
0.6
1
Aphidicolin (μM)
RIF1+
RIF1-
III
IV


A
+DOX
GFP-RIF1-L
GFP
31
+DOX
GFP-RIF1-S
GFP
B
siCon
siRIF1
GFP-RIF1-S
GFP-RIF1-L
GFP-RIF1-S
GFP-RIF1-S
GFP-RIF1-L
GFP-RIF1-L
DOX
- - - + + -
RIF1
GFP
Tubulin
C
Seed at low density +DOX induction
siRIF1
Count colonies
Aphidicolin
7 days
Day 1
3
4
5


A
PP1-interaction motifs
290
2180
2202
RIF1-L-pp1bs
RIF1-L
KKAAA
KKIAF
SAAK
SILK
RRASA
RRVSF
RIF1-L
31
B
siRIF1
siCon
GFP
GFP
GFP-RIF1-L
GFP-RIF1-L -pp1bs
DOX
+
+
+
+
RIF1
Ponceau
C
GFP-RIF1-L
GFP-RIF1-L-pp1bs
Relative CFU
1.5
1.0
0.5
0.0
**
0
0.3
0.6
1
Aphidicolin (μM)


A
mAC-RIF1
mAC-RIF1-L
mAC-RIF1-S
RIF1 KO
Number of 53BP1 NBs per cell
+Aphidicolin
-Aphidicolin
4+
3
2
1
0
0
20
40
60
80
100
% of cells